Compare NEXA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | SANA |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2017 | 2021 |
| Metric | NEXA | SANA |
|---|---|---|
| Price | $10.00 | $2.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $10.10 | $7.50 |
| AVG Volume (30 Days) | 648.1K | ★ 2.4M |
| Earning Date | 04-28-2026 | 03-03-2026 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $1.27 |
| 52 Week High | $14.94 | $6.55 |
| Indicator | NEXA | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 32.39 |
| Support Level | $8.79 | N/A |
| Resistance Level | $14.84 | $3.36 |
| Average True Range (ATR) | 0.61 | 0.19 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 35.55 | 6.65 |
Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.